Clinical Trials | June 23, 2026
Zealand Pharma’s petrelintide delivers double-digit weight loss in next-gen obesity treatment
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Nearly one in five women worldwide are now living with obesity
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
